Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole

Date
2016
Author
Gokturk, S.
Emrence, Zeliha
Besisik, F.
Soyer, O. M.
Kaymakoglu, S.
Akyuz, F.
Evirgen, S.
Ormeci, A.
Baran, B.
Ustek, D.
Demir, K.
Karaca, C.
Metadata
Show full item record
Abstract
OBJECTIVE: Cytochrome P450 2C19 (CYP2C19) polymorphisms play an important role in the metabolism of proton pump inhibitors. Rabeprazole is primarily metabolized via non-enzymatic pathways. In this study, we determined whether rabeprazole- and pantoprazole-based eradication treatments were influenced by CYP2C19 polymorphisms.
URI
http://hdl.handle.net/20.500.12627/146005
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85016996843&origin=inward
Collections